First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
PHASE1RecruitingINTERVENTIONAL
Enrollment
55
Participants
Timeline
Start Date
October 6, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
August 31, 2026
Conditions
Endocrine Neoplasia
Interventions
DRUG
4-[18F]Fluoro-1-Naphthol
By vein (IV)
Trial Locations (1)
77030
RECRUITING
MD Anderson Cancer Center, Houston
All Listed Sponsors
lead
M.D. Anderson Cancer Center
OTHER
NCT05335811 - First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging | Biotech Hunter | Biotech Hunter